An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization

Ostrander, K. D.; Bosch, H. William; Bondanza, Donna M.

doi:10.1016/s0939-6411(99)00049-1

Cited by 53 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59 The nebulized suspension will therefore generate larger aerosol droplets (ie, larger mass median aerodynamic diameter values) containing a smaller number of suspended particles (2-3 µm), whereas the aerosolized SSM droplets are smaller (with lower mass median aerodynamic diameter values) and contain many thousands of nanoparticles. 60 This postulation can be proved by using simple theoretical calculations, as suggested elsewhere. 60 The average droplet size produced by Pari LC nebulizers is approximately 4 to 5 µm according to the manufacturer.…”

Section: Aerodynamic Characterizationmentioning

confidence: 88%

“…60 This postulation can be proved by using simple theoretical calculations, as suggested elsewhere. 60 The average droplet size produced by Pari LC nebulizers is approximately 4 to 5 µm according to the manufacturer. As such, the maximum particle load for an average 4.5 µm diameter droplet generated by the nebulizers can be estimated using the following calculations:…”

Section: Aerodynamic Characterizationmentioning

confidence: 88%

See 1 more Smart Citation

Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations

Sahib¹,

Darwis²,

Peh³

et al. 2011

IJN

View full text Add to dashboard Cite

Background: Inhaled corticosteroids provide unique systems for local treatment of asthma or chronic obstructive pulmonary disease. However, the use of poorly soluble drugs for nebulization has been inadequate, and many patients rely on large doses to achieve optimal control of their disease. Theoretically, nanotechnology with a sustained-release formulation may provide a favorable therapeutic index. The aim of this study was to determine the feasibility of using sterically stabilized phospholipid nanomicelles of budesonide for pulmonary delivery via nebulization. Methods: PEG 5000 -DSPE polymeric micelles containing budesonide (BUD-SSMs) were prepared by the coprecipitation and reconstitution method, and the physicochemical and pharmacodynamic characteristics of BUD-SSMs were investigated. Results: The optimal concentration of solubilized budesonide at 5 mM PEG 5000 -DSPE was 605.71 ± 6.38 µg/mL, with a single-sized peak population determined by photon correlation spectroscopy and a particle size distribution of 21.51 ± 1.5 nm. The zeta potential of BUD-SSMs was −28.43 ± 1.98 mV. The percent entrapment efficiency, percent yield, and percent drug loading of the lyophilized formulations were 100.13% ± 1.09%, 97.98% ± 1.95%, and 2.01% ± 0.02%, respectively. Budesonide was found to be amorphous by differential scanning calorimetry, and had no chemical interaction with PEGylated polymer according to Fourier transform infrared spectroscopy. Transmission electron microscopic images of BUD-SSMs revealed spherical nanoparticles. BUD-SSMs exhibited prolonged dissolution behavior compared with Pulmicort Respules ® (P , 0.05). Aerodynamic characteristics indicated significantly higher deposition in the lungs compared with Pulmicort Respules ® . The mass median aerodynamic, geometric standard deviation, percent emitted dose, and the fine particle fraction were 2.83 ± 0.08 µm, 2.33 ± 0.04 µm, 59.13% ± 0.19%, and 52.31% ± 0.25%, respectively. Intratracheal administration of BUD-SSMs 23 hours before challenge (1 mg/kg) in an asthmatic/chronic obstructive pulmonary disease rat model led to a significant reduction in inflammatory cell counts (76.94 ± 5.11) in bronchoalveolar lavage fluid compared with administration of Pulmicort Respules ® (25.06 ± 6.91). Conclusion:The BUD-SSMs system might be advantageous for asthma or chronic obstructive pulmonary disease and other inflammatory airway diseases.

show abstract

Section: Aerodynamic Characterizationmentioning

confidence: 88%

Section: Aerodynamic Characterizationmentioning

confidence: 88%

Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations

Sahib¹,

Darwis²,

Peh³

et al. 2011

IJN

View full text Add to dashboard Cite

show abstract

“…Attributed to the many attractive characteristics of the inhaled nanoparticle formulation, a wide range of therapeutic agents have been formulated into inhalable nanoparticles, which are typically delivered by nebulization of the aqueous nanoparticulate suspension, as the nebulization delivery platform does not require a further dosing formulation. In this regard, bronchodilators and corticosteroids have been formulated into nanoparticles for inhaled therapies of asthma and COPD (15,16). Antibiotics have also been encapsulated into polymeric nanoparticles for inhaled tuberculosis therapy (17,18).…”

Section: Introductionmentioning

confidence: 99%

Antibacterial Efficacy of Inhalable Levofloxacin-Loaded Polymeric Nanoparticles Against E. coli Biofilm Cells: The Effect of Antibiotic Release Profile

2010

View full text Add to dashboard Cite

show abstract

“…64 The NanoCrystal TM BDP also showed in vitro aerosolisation efficiency using an ultrasound nebuliser. 65 High-pressure homogenization has been effective in preparing a nanosuspension of budesonide which exhibit long-term stability. With the particle size of approximately 500-600 nm, a very satisfactory respirable fraction of the jet-nebulised nanosuspension has been reported by Jacob and Müller.…”

Section: Nanosuspensionsmentioning

confidence: 99%

Alternatives to conventional suspensions for pulmonary drug delivery by nebulisers: A review

Amani

Ali

York

2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization

Cited by 53 publications

References 5 publications

Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations

Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations

Antibacterial Efficacy of Inhalable Levofloxacin-Loaded Polymeric Nanoparticles Against E. coli Biofilm Cells: The Effect of Antibiotic Release Profile

Alternatives to conventional suspensions for pulmonary drug delivery by nebulisers: A review

Contact Info

Product

Resources

About